NASDAQ:SVRA Savara (SVRA) Stock Price, News & Analysis → Elon’s New Device is About to Shock the World (From InvestorPlace) (Ad) Free SVRA Stock Alerts $4.66 -0.42 (-8.28%) (As of 05/10/2024 ET) Add Compare Share Share Today's Range$4.56▼$5.0050-Day Range$4.24▼$5.5952-Week Range$1.87▼$5.70Volume980,039 shsAverage Volume872,429 shsMarket Capitalization$643.21 millionP/E RatioN/ADividend YieldN/APrice Target$8.20 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Savara alerts: Email Address Savara MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside75.6% Upside$8.20 Price TargetShort InterestBearish6.37% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.13Based on 12 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.38) to ($0.30) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.47 out of 5 starsMedical Sector364th out of 915 stocksPharmaceutical Preparations Industry161st out of 426 stocks 3.5 Analyst's Opinion Consensus RatingSavara has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageSavara has only been the subject of 2 research reports in the past 90 days.Read more about Savara's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.37% of the float of Savara has been sold short.Short Interest Ratio / Days to CoverSavara has a short interest ratio ("days to cover") of 4.8.Change versus previous monthShort interest in Savara has recently increased by 28.36%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldSavara does not currently pay a dividend.Dividend GrowthSavara does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SVRA. Previous Next 1.7 News and Social Media Coverage News SentimentSavara has a news sentiment score of 0.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Savara this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for SVRA on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Savara to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Savara insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.58% of the stock of Savara is held by insiders.Percentage Held by Institutions87.93% of the stock of Savara is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Savara's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Savara are expected to grow in the coming year, from ($0.38) to ($0.30) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Savara is -14.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Savara is -14.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSavara has a P/B Ratio of 4.49. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Savara's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap ProfitsClaim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.Secure Your Spot Now About Savara Stock (NASDAQ:SVRA)Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.Read More SVRA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SVRA Stock News HeadlinesMay 10, 2024 | investorplace.comSVRA Stock Earnings: Savara Misses EPS for Q1 2024May 9, 2024 | businesswire.comSavara Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 10, 2024 | InvestorPlace (Ad)Elon’s New Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” May 8, 2024 | americanbankingnews.comSavara (NASDAQ:SVRA) Rating Reiterated by JMP SecuritiesMay 7, 2024 | businesswire.comSavara to Present at the Citizens JMP Life Sciences ConferenceMay 7, 2024 | markets.businessinsider.comOppenheimer Keeps Their Buy Rating on Savara (SVRA)May 3, 2024 | markets.businessinsider.comOptimistic Buy Rating on Savara Amid Anticipated IMPALA-2 Trial SuccessMay 2, 2024 | msn.comFormer state minister late Vishnu Savara's son Hemant is BJP's Palghar candidateMay 10, 2024 | InvestorPlace (Ad)Elon’s New Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” April 25, 2024 | finance.yahoo.comSavara Inc. (SVRA) Stock Price, News, Quote & History - Yahoo FinanceApril 20, 2024 | seekingalpha.comFYBR, BCRX and SABR are among after hour moversApril 11, 2024 | markets.businessinsider.comOptimistic Buy Rating for Savara Based on Molgramostim’s Market Potential and Study OutcomesMarch 22, 2024 | businesswire.comSavara Announces New Employment Inducement GrantMarch 13, 2024 | msn.comSavara Inc. Reports Increased Expenses, Anticipates Positive Data from IMPALA-2 TrialMarch 11, 2024 | msn.comFDA lifts partial hold on Nurix Phase 1 study for NX-2127March 11, 2024 | markets.businessinsider.comBuy Rating Affirmed: Anticipating IMPALA-2 Trial Success and aPAP Treatment Breakthrough with MolgramostimMarch 10, 2024 | finance.yahoo.comSVRA Jul 2024 7.500 callMarch 8, 2024 | markets.businessinsider.comOptimistic Buy Rating for Savara on Molgramostim’s Market Potential and Strong FinancialsMarch 7, 2024 | msn.comSVRA Stock Earnings: Savara Beats EPS for Q4 2023March 7, 2024 | finance.yahoo.comSavara Reports Fourth Quarter/Year-End 2023 Financial Results and Provides Business UpdateMarch 6, 2024 | usatoday.comBest penny stocks of March 2024March 6, 2024 | finance.yahoo.comSavara to Present at the Barclays 26th Annual Global Healthcare ConferenceMarch 1, 2024 | markets.businessinsider.comPiper Sandler Keeps Their Buy Rating on Savara (SVRA)February 24, 2024 | msn.comSavara (SVRA) Price Target Increased by 22.98% to 7.21February 22, 2024 | au.finance.yahoo.comSavara Inc. (YB4P.F)February 21, 2024 | msn.comSee Leaked Details of Bensoul, Nviiri and Savara's Music ProjectFebruary 20, 2024 | finance.yahoo.comSavara Inc. (NASDAQ:SVRA): Are Analysts Optimistic?See More Headlines Receive SVRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Savara and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/07/2024Today5/10/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:SVRA Previous SymbolAMEX:ANX CUSIPN/A CIK1160308 Webwww.savarapharma.com Phone512-614-1848Fax858-552-0876EmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Target$8.20 High Stock Price Target$16.00 Low Stock Price Target$4.00 Potential Upside/Downside+68.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.33) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-54,700,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-46.27% Return on Assets-35.94% Debt Debt-to-Equity Ratio0.19 Current Ratio15.66 Quick Ratio15.66 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.04 per share Price / Book4.68Miscellaneous Outstanding Shares138,177,000Free Float131,848,000Market Cap$672.92 million OptionableOptionable Beta0.73 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesRobert N. Neville (Age 51)Chairman of the Board, Chief Executive Officer Taneli Jouhikainen (Age 51)President, Chief Operating Officer David L. Lowrance (Age 50)Chief Financial Officer Nevan C. Elam (Age 49)Independent Director Richard J. Hawkins (Age 68)Independent Director Joseph S. McCracken Ph.D. (Age 64)Independent Director Matthew Pauls J.D. (Age 46)Independent Director Yuri Pikover (Age 56)Independent Director More ExecutivesKey CompetitorsDisc MedicineNASDAQ:IRONAurinia PharmaceuticalsNASDAQ:AUPHPureTech HealthNASDAQ:PRTCCogent BiosciencesNASDAQ:COGTArcturus TherapeuticsNASDAQ:ARCTView All CompetitorsInsiders & InstitutionsProShare Advisors LLCBought 2,114 shares on 5/8/2024Ownership: 0.019%Swiss National BankBought 147,000 shares on 5/7/2024Ownership: 0.106%Susquehanna Fundamental Investments LLCBought 79,073 shares on 5/7/2024Ownership: 0.057%SG Americas Securities LLCSold 16,145 shares on 5/7/2024Ownership: 0.024%Jennison Associates LLCBought 26,613 shares on 5/2/2024Ownership: 6.399%View All Insider TransactionsView All Institutional Transactions SVRA Stock Analysis - Frequently Asked Questions Should I buy or sell Savara stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Savara in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SVRA shares. View SVRA analyst ratings or view top-rated stocks. What is Savara's stock price target for 2024? 5 Wall Street research analysts have issued 1-year price objectives for Savara's shares. Their SVRA share price targets range from $4.00 to $16.00. On average, they anticipate the company's stock price to reach $8.20 in the next year. This suggests a possible upside of 75.6% from the stock's current price. View analysts price targets for SVRA or view top-rated stocks among Wall Street analysts. How have SVRA shares performed in 2024? Savara's stock was trading at $4.70 on January 1st, 2024. Since then, SVRA shares have decreased by 0.6% and is now trading at $4.67. View the best growth stocks for 2024 here. Are investors shorting Savara? Savara saw a increase in short interest in the month of April. As of April 30th, there was short interest totaling 4,300,000 shares, an increase of 28.4% from the April 15th total of 3,350,000 shares. Based on an average daily volume of 901,300 shares, the short-interest ratio is presently 4.8 days. Currently, 6.4% of the company's shares are short sold. View Savara's Short Interest. When is Savara's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our SVRA earnings forecast. How were Savara's earnings last quarter? Savara Inc (NASDAQ:SVRA) posted its earnings results on Thursday, March, 7th. The company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.02. What other stocks do shareholders of Savara own? Based on aggregate information from My MarketBeat watchlists, some companies that other Savara investors own include BioLineRx (BLRX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Geron (GERN), Inovio Pharmaceuticals (INO), T2 Biosystems (TTOO), Verastem (VSTM), Agile Therapeutics (AGRX) and Corbus Pharmaceuticals (CRBP). Who are Savara's major shareholders? Savara's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Jennison Associates LLC (6.40%), Swiss National Bank (0.11%), Susquehanna Fundamental Investments LLC (0.06%), BNP Paribas Financial Markets (0.05%), SG Americas Securities LLC (0.02%) and China Universal Asset Management Co. Ltd. (0.02%). Insiders that own company stock include Badrul A Chowdhury, David A Ramsay, David L Lowrance, Matthew Pauls, Nevan C Elam, Raymond Dennis Pratt and Rick Yang. View institutional ownership trends. How do I buy shares of Savara? Shares of SVRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SVRA) was last updated on 5/10/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaGold Set to EXPLODE!Gold Safe ExchangeCharles Payne Demystifies OptionsUnstoppable ProsperityShocking: One AI startup's revenue could surge 4,735%Manward PressForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingHe Is Giving Away BitcoinCrypto Swap ProfitsMissed NVDA? Buy this AI stock NOWChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Savara Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
